Genetic diversity and population structure of genes encoding vaccine candidate antigens of Plasmodium vivax

Malaria Journal

Volumn 11, Issue , 2012, Pages

  Chenet, Stella M ^a,b,c   Tapia, Lorena L ^a   Escalante, Ananias A ^b,c   Durand, Salomon ^a   Lucas, Carmen ^a   Bacon, David J ^a,d  

^a California   (Peru)

^b ARIZONA STATE UNIVERSITY   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

^d NAVAL RESEARCH LABORATORY   (United States)

Author keywords

Haplotypes; Malaria; Plasmodium vivax; Vaccine candidates

Indexed keywords

APICAL MEMBRANE ANTIGEN 1; CIRCUMSPOROZOITE PROTEIN; DUFFY BINDING PROTEIN; MEROZOITE SURFACE PROTEIN 1; THROMBOSPONDIN; MALARIA VACCINE; PARASITE ANTIGEN;

ANTIGEN DETECTION; ARTICLE; GENE FREQUENCY; GENETIC VARIABILITY; HAPLOTYPE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARASITE ISOLATION; PLASMODIUM VIVAX; POPULATION STRUCTURE; SEQUENCE ALIGNMENT; SPECIES DISTRIBUTION; SPECIES DIVERSITY; UNINDEXED SEQUENCE; AMINO ACID SEQUENCE; ANTIGENIC VARIATION; ASIA; GENETIC POLYMORPHISM; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MOLECULAR GENETICS; PACIFIC ISLANDS; PHYLOGEOGRAPHY; SOUTH AND CENTRAL AMERICA;

AMINO ACID SEQUENCE; ANTIGENIC VARIATION; ANTIGENS, PROTOZOAN; ASIA; HAPLOTYPES; LATIN AMERICA; MALARIA VACCINES; MOLECULAR SEQUENCE DATA; OCEANIA; PHYLOGEOGRAPHY; PLASMODIUM VIVAX; POLYMORPHISM, GENETIC;

EID: 84858023797     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-11-68     Document Type: Article

References (64)

1. Current status of Plasmodium vivax vaccine. Arevalo-Herrera M, Chitnis C, Herrera S, Hum Vaccin 2010 6 124 132 10.4161/hv.6.1.9931 20009526
2. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M, Lampah DA, Price RN, PLoS Med 2008 5 128 10.1371/journal.pmed.0050128 18563962 (Pubitemid 351919110)
3. Severe vivax malaria: newly recognised or rediscovered. Rogerson SJ, Carter R, PLoS Med 2008 5 136 10.1371/journal.pmed.0050136 18563965 (Pubitemid 351919107)
4. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Price RN, Douglas NM, Anstey NM, Curr Opin Infect Dis 2009 22 430 435 10.1097/QCO.0b013e32832f14c1 19571748
5. Report on Situation of Malaria in the Americas, PAHO. 2008
6. Simulation of the cost-effectiveness of malaria vaccines. Tediosi F, Maire N, Penny M, Studer A, Smith TA, Malar J 2009 8 127 10.1186/1475-2875-8-127 19505328
7. Malaria vaccine: a current perspective. Sharma S, Pathak S, J Vector Borne Dis 2008 45 1 20 18814384 (Pubitemid 351345753)
8. Advances and challenges in malaria vaccine development. Crompton PD, Pierce SK, Miller LH, J Clin Invest 2010 120 4168 4178 10.1172/JCI44423 21123952
9. Migration through host cells: the first steps of Plasmodium sporozoites in the mammalian host. Mota MM, Rodriguez A, Cell Microbiol 2004 6 1113 1118 10.1111/j.1462-5822.2004.00460.x 15527491 (Pubitemid 39517481)
10. Sequence variation in the circumsporozoite protein gene of Plasmodium vivax appears to be regionally biased. Mann VH, Huang T, Cheng Q, Saul A, Mol Biochem Parasitol 1994 68 45 52 10.1016/0166-6851(94)00148-0 7891747 (Pubitemid 24358616)
11. Circumsporozoite protein heterogeneity in the human malaria parasite Plasmodium vivax. Rosenberg R, Wirtz RA, Lanar DE, Sattabongkot J, Hall T, Waters AP, Prasittisuk C, Science 1989 245 973 976 10.1126/science.2672336 2672336 (Pubitemid 19224827)
12. Circumsporozoite genotyping of global isolates of Plasmodium vivax from dried blood specimens. Kain KC, Brown AE, Webster HK, Wirtz RA, Keystone JS, Rodriguez MH, Kinahan J, Rowland M, Lanar DE, J Clin Microbiol 1992 30 1863 1866 1629344
13. Identification of Plasmodium vivax-like human malaria parasite. Qari SH, Shi YP, Goldman IF, Udhayakumar V, Alpers MP, Collins WE, Lal AA, Lancet 1993 341 780 783 10.1016/0140-6736(93)90559-Y 8095999 (Pubitemid 23096285)
14. Circumsporozoite protein gene of Plasmodium simiu, a Plasmodium vivax-like monkey malaria parasite. Goldman IF, Qari SH, Millet PG, Collins WE, Lal AA, Mol Biochem Parasitol 1993 57 177 180 10.1016/0166-6851(93)90257-X 8426613 (Pubitemid 223039597)
15. Efficacy of RTS, S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, Ballou WR, Conway DJ, Reece WH, Gothard P, Yamuah L, Delchambre M, Voss G, Greenwood BM, Hill A, McAdam KP, Tornieporth N, Cohen JD, Doherty T, S Malaria Vaccine Trial Team, Lancet 2001 358 1927 1934 10.1016/S0140-6736(01)06957-4 11747915 (Pubitemid 34072872)
16. Efficacy of the RTS, S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, Mandomando I, Spiessens B, Guinovart C, Espasa M, Bassat Q, Aide P, Ofori-Anyinam O, Navia MM, Corachan S, Ceuppens M, Dubois MC, Demoitié MA, Dubovsky F, Menéndez C, Tornieporth N, Ballou WR, Thompson R, Cohen J, Lancet 2004 364 1411 1420 10.1016/S0140-6736(04)17223-1 15488216 (Pubitemid 39370716)
17. Clinical trials to estimate the efficacy of preventive interventions against malaria in paediatric populations: a methodological review. Moorthy VS, Reed Z, Smith PG, Malar J 2009 8 23 10.1186/1475-2875-8-23 19208236
18. Safety and immunogenicity of RTS, S/AS02D malaria vaccine in infants. Abdulla S, Oberholzer R, Juma O, Kubhoja S, Machera F, Membi C, Omari S, Urassa A, Mshinda H, Jumanne A, Salim N, Shomari M, Aebi T, Schellenberg DM, Carter T, Villafana T, Demoitié MA, Dubois MC, Leach A, Lievens M, Vekemans J, Cohen J, Ballou WR, Tanner M, N Engl J Med 2008 359 2533 2544 10.1056/NEJMoa0807773 19064623
19. From the circumsporozoite protein to the RTS, S/AS candidate vaccine. Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A, Hum Vaccin 2010 6 90 96 10.4161/hv.6.1.9677 19806009
20. TRAP is necessary for gliding motility and infectivity of plasmodium sporozoites. Sultan AA, Thathy V, Frevert U, Robson KJ, Crisanti A, Nussenzweig V, Nussenzweig RS, Menard R, Cell 1997 90 511 522 10.1016/S0092-8674(00)80511-5 9267031 (Pubitemid 27347241)
21. Plasmodium falciparum: genetic and immunogenic characterisation of the rhoptry neck protein PfRON4. Morahan BJ, Sallmann GB, Huestis R, Dubljevic V, Waller KL, Exp Parasitol 2009 122 280 288 10.1016/j.exppara.2009.04.013 19442663
22. Diversity in the thrombospondin-related adhesive protein gene (TRAP) of Plasmodium vivax. Putaporntip C, Jongwutiwes S, Tia T, Ferreira MU, Kanbara H, Tanabe K, Gene 2001 268 97 104 10.1016/S0378-1119(01)00425-5 11368905 (Pubitemid 32463793)
23. Construction and immunogenicity of DNA vaccine plasmids encoding four Plasmodium vivax candidate vaccine antigens. Rogers WO, Gowda K, Hoffman SL, Vaccine 1999 17 3136 3144 10.1016/S0264-410X(99)00146-2 10462250 (Pubitemid 29366995)
24. Plasmodium vivax thrombospondin related adhesion protein: immunogenicity and protective efficacy in rodents and Aotus monkeys. Castellanos A, Arevalo-Herrera M, Restrepo N, Gulloso L, Corradin G, Herrera S, Mem Inst Oswaldo Cruz 2007 102 411 416 10.1590/S0074-02762007005000047 17568948 (Pubitemid 46869339)
25. The erythrocyte binding motif of Plasmodium vivax duffy binding protein is highly polymorphic and functionally conserved in isolates from Papua New Guinea. Xainli J, Adams JH, King CL, Mol Biochem Parasitol 2000 111 253 260 10.1016/S0166-6851(00)00315-7 11163434 (Pubitemid 32121669)
26. Plasmodium vivax Duffy binding protein peptides specifically bind to reticulocytes. Ocampo M, Vera R, Rodriguez LE, Curtidor H, Urquiza M, Suarez J, Garcia J, Puentes A, Lopez R, Trujillo M, Torres E, Patarroyo ME, Peptides 2002 23 13 22 10.1016/S0196-9781(01)00574-5 11814613 (Pubitemid 34113759)
27. Mapping epitopes of the Plasmodium vivax Duffy binding protein with naturally acquired inhibitory antibodies. Chootong P, Ntumngia FB, VanBuskirk KM, Xainli J, Cole-Tobian JL, Campbell CO, Fraser TS, King CL, Adams JH, Infect Immun 2010 78 1089 1095 10.1128/IAI.01036-09 20008533
28. Structural basis for Duffy recognition by the malaria parasite Duffy-binding-like domain. Singh SK, Hora R, Belrhali H, Chitnis CE, Sharma A, Malar J 2006 493 741 744 (Pubitemid 43237622)
29. A multifunctional serine protease primes the malaria parasite for red blood cell invasion. Koussis K, Withers-Martinez C, Yeoh S, Child M, Hackett F, Knuepfer E, Juliano L, Woehlbier U, Bujard H, Blackman MJ, EMBO J 2009 28 725 735 10.1038/emboj.2009.22 19214190
30. Plasmodium vivax promiscuous T-helper epitopes defined and evaluated as linear peptide chimera immunogens. Caro-Aguilar I, Rodriguez A, Calvo-Calle JM, Guzman F, De la Vega P, Patarroyo ME, Galinski MR, Moreno A, Infect Immun 2002 70 3479 3492 10.1128/IAI.70.7.3479-3492.2002 12065487 (Pubitemid 34665984)
31. Expression, polymorphism analysis, reticulocyte binding and serological reactivity of two Plasmodium vivax MSP-1 protein recombinant fragments. Espinosa AM, Sierra AY, Barrero CA, Cepeda LA, Cantor EM, Lombo TB, Guzman F, Avila SJ, Patarroyo MA, Vaccine 2003 21 1033 1043 10.1016/S0264-410X(02)00660-6 12559776 (Pubitemid 36139931)
32. Splenectomised and spleen intact Aotus monkeys' immune response to Plasmodium viva MSP-1 protein fragments and their high activity binding peptides. Sierra AY, Barrero CA, Rodriguez R, Silva Y, Moncada C, Vanegas M, Patarroyo MA, Vaccine 2003 21 4133 4144 10.1016/S0264-410X(03)00455-9 14505893 (Pubitemid 37130262)
33. A recombinant vaccine based on domain II of Plasmodium vivax Apical Membrane Antigen 1 induces high antibody titres in mice. Gentil F, Bargieri DY, Leite JA, Francoso KS, Patricio MB, Espindola NM, Vaz AJ, Palatnik-de-Sousa CB, Rodrigues MM, Costa FT, Soares IS, Vaccine 2010 28 6183 6190 10.1016/j.vaccine.2010.07.017 20654667
34. Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children. Cech PG, Aebi T, Abdallah MS, Mpina M, Machunda EB, Westerfeld N, Stoffel SA, Zurbriggen R, Pluschke G, Tanner M, Daubenberger C, Genton B, Abdulla S, PLoS One 2011 6 22273 10.1371/journal.pone.0022273 21799810
35. Geographical structure of diversity and differences between symptomatic and asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1. Cortes A, Mellombo M, Mueller I, Benet A, Reeder JC, Anders RF, Infect Immun 2003 71 1416 1426 10.1128/IAI.71.3.1416-1426.2003 12595459 (Pubitemid 36254328)
36. Sequence diversity and natural selection at domain I of the apical membrane antigen 1 among Indian Plasmodium falciparum populations. Garg S, Alam MT, Das MK, Dev V, Kumar A, Dash AP, Sharma YD, Malar J 2007 6 154 10.1186/1475-2875-6-154 18031585
37. Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes. Crewther PE, Matthew ML, Flegg RH, Anders RF, Infect Immun 1996 64 3310 3317 8757869 (Pubitemid 26256181)
38. Aspects of immunity for the AMA-1 family of molecules in humans and non-human primates malarias. Thomas AW, Narum D, Waters AP, Trape JF, Rogier C, Goncalves A, Rosario V, Druilhe P, Mitchell GH, Dennis D, Mem Inst Oswaldo Cruz 1994 89 Suppl 2 67 70 7565135
39. Natural human antibody responses to Plasmodium vivax apical membrane antigen 1 under low transmission and unstable malaria conditions in Sri Lanka. Wickramarachchi T, Premaratne PH, Perera KL, Bandara S, Kocken CH, Thomas AW, Handunnetti SM, Udagama-Randeniya PV, Infect Immun 2006 74 798 801 10.1128/IAI.74.1.798-801.2006 16369044 (Pubitemid 43023143)
40. 19on the innate immune response. Bueno LL, Fujiwara RT, Soares IS, Braga EM, Vaccine 2008 26 1204 1213 10.1016/j.vaccine.2007.12.031 18242795
41. Plasmodium vivax sub-patent infections after radical treatment are common in Peruvian patients: results of a 1-year prospective cohort study. Van den Eede P, Soto-Calle VE, Delgado C, Gamboa D, Grande T, Rodriguez H, Llanos-Cuentas A, Anne J, D'Alessandro U, Erhart A, PLoS One 2011 6 16257 10.1371/journal.pone.0016257 21297986
42. Practical PCR genotyping protocols for Plasmodium vivax using Pcsp and Pmsp1. Imwong M, Pukrittayakamee S, Gruner AC, Renia L, Letourneur F, Looareesuwan S, White NJ, Snounou G, Malar J 2005 4 20 10.1186/1475-2875-4-20 15854233 (Pubitemid 40918738)
43. Genetic polymorphism of the Duffy receptor binding domain of Plasmodium vivax in Colombian wild isolates. Ampudia E, Patarroyo MA, Patarroyo ME, Murillo LA, Mol Biochem Parasitol 1996 78 269 272 10.1016/S0166-6851(96)02611-4 8813697 (Pubitemid 26202342)
44. Sequence analysis of the apical membrane antigen I (AMA-1) of Plasmodium vivax. Cheng Q, Saul A, Mol Biochem Parasitol 1994 65 183 187 10.1016/0166-6851(94)90127-9 7935625 (Pubitemid 24232828)
45. MEGA4: Molecular evolutionary genetics analysis (mega) software version 4.0. Tamura K, Dudley J, Nei M, Kumar S, Mol Biol Evol 2007 24 1596 1599 10.1093/molbev/msm092 17488738 (Pubitemid 47236692)
46. DnaSP v5: a software for comprehensive analysis of DNA polymorphism data. Librado P, Rozas J, Bioinformatics 2009 25 1451 1452 10.1093/bioinformatics/ btp187 19346325
47. Assessing the effect of natural selection in malaria parasites. Escalante AA, Cornejo OE, Rojas A, Udhayakumar V, Lal AA, Trends Parasitol 2004 20 388 395 10.1016/j.pt.2004.06.002 15246323 (Pubitemid 38916529)
48. Inference of population structure using multilocus genotype data. Pritchard JK, Stephens M, Donnelly P, Genetics 2000 155 945 959 10835412 (Pubitemid 30397141)
49. CLUMPP: a cluster matching and permutation program for dealing with label switching and multimodality in analysis of population structure. Jakobsson M, Rosenberg NA, Bioinformatics 2007 23 1801 1806 10.1093/bioinformatics/btm233 17485429 (Pubitemid 47250313)
50. Efficacy of chloroquine, amodiaquine, sulphadoxine-pyrimethamine and combination therapy with artesunate in Mozambican children with non-complicated malaria. Abacassamo F, Enosse S, Aponte JJ, Gomez-Olive FX, Quinto L, Mabunda S, Barreto A, Magnussen P, Ronn AM, Thompson R, Alonso PL, Trop Med Int Health 2004 9 200 208 10.1046/j.1365-3156.2003.01182.x 15040556 (Pubitemid 38250806)
51. A new statistic for detecting genetic differentiation. Hudson RR, Genetics 2000 155 2011 2014 10924493 (Pubitemid 30626415)
52. Circumsporozoite protein gene diversity among temperate and tropical Plasmodium vivax isolates from Iran. Zakeri S, Abouie Mehrizi A, Djadid ND, Snounou G, Trop Med Int Health 2006 11 729 737 10.1111/j.1365-3156.2006.01613.x 16640626
53. Acquired immune response to defined Plasmodium viva antigens in individuals residing in northern India. Seth RK, Bhat AA, Rao DN, Biswas S, Microbes Infect Institut Pasteur 2010 12 199 206 10.1016/j.micinf.2009.12.006
54. Structural and functional properties of region II-plus of the malaria circumsporozoite protein. Sinnis PCP, Fenyo D, Chait BT, Cerami C, Nussenzweig V, J Exp Med 1994 180 297 306 10.1084/jem.180.1.297 8006589 (Pubitemid 24181078)
55. Variants of the Plasmodium vivax circumsporozoite protein (VK210 and VK247) in Colombian isolates. Gonzalez JM, Hurtado S, Arevalo-Herrera M, Herrera S, Mem Inst Oswaldo Cruz 2001 96 709 712 10.1590/S0074-02762001000500023 11500776 (Pubitemid 33704179)
56. Molecular epidemiology of Plasmodium vivax in the State of Amazonas, Brazil. Santos-Ciminera PD, Alecrim MG, Roberts DR, Quinnan GV Jr, Acta Trop 2007 102 38 46 10.1016/j.actatropica.2007.02.013 17397788 (Pubitemid 46809832)
57. A conserved peptide sequence of the Plasmodium falciparum circumsporozoite protein and antipeptide antibodies inhibit Plasmodium berghei sporozoite invasion of Hep-G2 cells and protect immunized mice against P. berghei sporozoite challenge. Chatterjee S, Wery M, Sharma P, Chauhan VS, Infect Immun 1995 63 4375 4381 7591073
58. Function of region I and II adhesive motifs of Plasmodium falciparum circumsporozoite protein in sporozoite motility and infectivity. Tewari R, Spaccapelo R, Bistoni F, Holder AA, Crisanti A, J Biol Chem 2002 277 47613 47618 10.1074/jbc.M208453200 12244064 (Pubitemid 36159282)
59. Evaluation of the antigenicity of universal epitopes from PvDBPII in individuals exposed to Plasmodium vivax malaria. Martinez P, Lopez C, Saravia C, Vanegas M, Patarroyo MA, Microbes Infect 2010 12 1188 1197 10.1016/j.micinf. 2010.08.007 20804855
60. Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. Takala SL, Coulibaly D, Thera MA, Batchelor AH, Cummings MP, Escalante AA, Ouattara A, Traoré K, Niangaly A, Djimdé AA, Doumbo OK, Plowe CV, Sci Transl Med 2009 1 2ra5 10.1126/scitranslmed.3000257 20165550
61. A statistical test for detecting geographic subdivision. Hudson RR, Boos DD, Kaplan NL, Mol Biol Evol 1992 9 138 151 1552836
62. Contrasting population structures of the genes encoding ten leading vaccine-candidate antigens of the human malaria parasite, Plasmodium falciparum. Barry AE, Schultz L, Buckee CO, Reeder JC, PLoS One 2009 4 8497 10.1371/journal.pone.0008497 20041125
63. Worldwide genetic variability of the Duffy binding protein: insights into Plasmodium vivax vaccine development. Nobrega de Sousa T, Carvalho LH, Alves de Brito CF, PLoS One 2011 6 22944 10.1371/journal.pone.0022944 21829672
64. Clustered local transmission and asymptomatic Plasmodium falciparum and Plasmodium vivax malaria infections in a recently emerged, hypoendemic Peruvian Amazon community. Branch O, Casapia WM, Gamboa DV, Hernandez JN, Alava FF, Roncal N, Alvarez E, Perez EJ, Gotuzzo E, Malar J 2005 4 27 10.1186/1475-2875-4- 27 15975146 (Pubitemid 41214251)